Cargando…
Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587416/ https://www.ncbi.nlm.nih.gov/pubmed/33134869 http://dx.doi.org/10.1097/HS9.0000000000000485 |
| _version_ | 1783600170442686464 |
|---|---|
| author | Gisslinger, Heinz Klade, Christoph Georgiev, Pencho Krochmalczyk, Dorota Gercheva-Kyuchukova, Liana Egyed, Miklos Rossiev, Viktor Dulicek, Petr Illes, Arpad Pylypenko, Halyna Sivcheva, Lylia Mayer, Jiri Yablokova, Vera Krejcy, Kurt Hasselbalch, Hans C. Kralovics, Robert Kiladjian, Jean-Jacques |
| author_facet | Gisslinger, Heinz Klade, Christoph Georgiev, Pencho Krochmalczyk, Dorota Gercheva-Kyuchukova, Liana Egyed, Miklos Rossiev, Viktor Dulicek, Petr Illes, Arpad Pylypenko, Halyna Sivcheva, Lylia Mayer, Jiri Yablokova, Vera Krejcy, Kurt Hasselbalch, Hans C. Kralovics, Robert Kiladjian, Jean-Jacques |
| author_sort | Gisslinger, Heinz |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7587416 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75874162020-10-29 Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups Gisslinger, Heinz Klade, Christoph Georgiev, Pencho Krochmalczyk, Dorota Gercheva-Kyuchukova, Liana Egyed, Miklos Rossiev, Viktor Dulicek, Petr Illes, Arpad Pylypenko, Halyna Sivcheva, Lylia Mayer, Jiri Yablokova, Vera Krejcy, Kurt Hasselbalch, Hans C. Kralovics, Robert Kiladjian, Jean-Jacques Hemasphere Letter Lippincott Williams & Wilkins 2020-10-20 /pmc/articles/PMC7587416/ /pubmed/33134869 http://dx.doi.org/10.1097/HS9.0000000000000485 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
| spellingShingle | Letter Gisslinger, Heinz Klade, Christoph Georgiev, Pencho Krochmalczyk, Dorota Gercheva-Kyuchukova, Liana Egyed, Miklos Rossiev, Viktor Dulicek, Petr Illes, Arpad Pylypenko, Halyna Sivcheva, Lylia Mayer, Jiri Yablokova, Vera Krejcy, Kurt Hasselbalch, Hans C. Kralovics, Robert Kiladjian, Jean-Jacques Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups |
| title | Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups |
| title_full | Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups |
| title_fullStr | Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups |
| title_full_unstemmed | Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups |
| title_short | Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups |
| title_sort | ropeginterferon alfa-2b: efficacy and safety in different age groups |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587416/ https://www.ncbi.nlm.nih.gov/pubmed/33134869 http://dx.doi.org/10.1097/HS9.0000000000000485 |
| work_keys_str_mv | AT gisslingerheinz ropeginterferonalfa2befficacyandsafetyindifferentagegroups AT kladechristoph ropeginterferonalfa2befficacyandsafetyindifferentagegroups AT georgievpencho ropeginterferonalfa2befficacyandsafetyindifferentagegroups AT krochmalczykdorota ropeginterferonalfa2befficacyandsafetyindifferentagegroups AT gerchevakyuchukovaliana ropeginterferonalfa2befficacyandsafetyindifferentagegroups AT egyedmiklos ropeginterferonalfa2befficacyandsafetyindifferentagegroups AT rossievviktor ropeginterferonalfa2befficacyandsafetyindifferentagegroups AT dulicekpetr ropeginterferonalfa2befficacyandsafetyindifferentagegroups AT illesarpad ropeginterferonalfa2befficacyandsafetyindifferentagegroups AT pylypenkohalyna ropeginterferonalfa2befficacyandsafetyindifferentagegroups AT sivchevalylia ropeginterferonalfa2befficacyandsafetyindifferentagegroups AT mayerjiri ropeginterferonalfa2befficacyandsafetyindifferentagegroups AT yablokovavera ropeginterferonalfa2befficacyandsafetyindifferentagegroups AT krejcykurt ropeginterferonalfa2befficacyandsafetyindifferentagegroups AT hasselbalchhansc ropeginterferonalfa2befficacyandsafetyindifferentagegroups AT kralovicsrobert ropeginterferonalfa2befficacyandsafetyindifferentagegroups AT kiladjianjeanjacques ropeginterferonalfa2befficacyandsafetyindifferentagegroups |